Finnish healthtech startup CurifyLabs raises €12m to bring personalised medicine to more patients worldwide
Helsinki-based CurifyLabs, which uses 3D-printing technology to help pharmacies compound custom-dosed medicines, has closed a €12 million Series A round — its second raise in just over a year — to fuel its expansion across the United States and beyond.
Text by Martti Asikainen, 9.7.2026 | Photo by Adobe Stock Photos
CurifyLabs, a Finnish health technology company founded in Helsinki in 2021, announced on 6 July that it has raised €12 million in Series A funding, co-led by Nordic investors Sandwater and HealthCap, with participation from Finnish state investor Tesi and existing backer Lifeline Ventures, alongside customers and employees in the US.
The round follows a €6.7 million raise in May 2025 and brings the company’s total funding past €16 million — a strong signal of investor confidence in Finnish life sciences innovation.
CurifyLabs’ technology addresses a problem that affects millions of patients: many medicines simply aren’t available in the exact dose or form a patient needs. Children, elderly patients, and people with rare conditions often require custom-compounded medication, a process that has traditionally been slow and manual.
Solving a real gap in modern medicine
CurifyLabs’ Compounding System Solution changes that by combining proprietary software, pharmaceutical-grade ingredient bases, and its own 3D-printing hardware — the PharmaPrinter — to produce precise, patient-specific doses with built-in quality checks.
Its newest system, the PharmaPrinter Aurum, compounds medicine up to nine times faster than manual methods, is ISO 13485 certified, and is designed to meet FDA standards for non-sterile compounding — engineering credentials that reflect the rigour behind the company’s Finnish scientific roots.
The technology is already in daily use in pharmacies across 21 US states and in Europe, where it helps dispense thousands of personalised doses every day.
Finnish scientific expertise at the core
CurifyLabs was founded by CEO Charlotta Topelius alongside Niklas Sandler, a professor of pharmaceutical technology at Åbo Akademi University who has spent over a decade researching automated compounding — a partnership that pairs deep Finnish academic research with entrepreneurial drive.
According to Topelius, investment reflects the conviction their partners have in what they’re building. “We have set a high bar for clinical rigour, product quality, and customer support, and this funding gives us the resources to raise that bar further”, she says.
HealthCap’s Daniel Karsberg, whose firm has backed more than 136 life sciences companies, said the CurifyLabs team stood out for combining “scientific depth with real-world execution.”
Tesi’s Joni Karsikas was even more direct about what the round represents for the country. “Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage”, he stated.
The confidence extends across the investor group. Morten E. Iversen of Sandwater said CurifyLabs had “built something rare — technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on.”
Strengthening the supply chain
The new funding will go towards expanding CurifyLabs’ US operations, strengthening its supply chain, and accelerating product development — growth that builds on the company’s earlier €5.6 million EU-funded RoboPharma project to modernise personalised medicine manufacturing.
With the global compounding pharmacy market valued at around $15 billion and growing steadily, CurifyLabs’ rapid rise positions it as one of the clearest examples yet of Finnish deep-tech innovation scaling to a genuinely global stage.
CurifyLabs’ raise also lands amid a broader surge of momentum in European health technology, with 2026 already seeing a wave of substantial funding rounds for companies working on personalised health, diagnostics, and clinical innovation across the continent.
